
Opinion|Videos|April 9, 2025
Defining Hypercortisolism and Its Impact on Physical and Mental Health
Experts discuss the physical impact of hypercortisolism on a patient, how the condition affects overall health, and the long-term risks that remain even after remission, including incomplete resolution of comorbidities, reduced quality of life, and increased mortality risk.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the physical impact of hypercortisolism on a patient? How does this condition affect patients’ overall health?
- How can hypercortisolism affect a patient’s long-term health and quality of life?
- Long-term risks remain for patients even if hypercortisolism remission is achieved, including incomplete resolution of comorbidities, reduced quality of life, and increased mortality risk.
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

